NCT00238277 is a Phase 2 clinical trial of temozolomide in Brain and Central Nervous System Tumors, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Who is sponsoring NCT00238277?

NCT00238277 is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

What drugs are being tested in NCT00238277?

Interventions in NCT00238277: temozolomide, adjuvant therapy, chemotherapy, radiation therapy.

What condition does NCT00238277 study?

NCT00238277 studies Brain and Central Nervous System Tumors.

Is NCT00238277 still recruiting?

NCT00238277 is currently terminated. Last updated 27 June 2018.

Last reviewed 2018-06-27 · How we verify

NCT00238277

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Temozolomide During and After Radiation Therapy in Treating Patients Who Have Undergone Previous Surgery and Placement of Gliadel Wafers for Newly Diagnosed Glioblastoma Multiforme

Terminated Phase 2 Last updated 27 June 2018

What this trial tests

Phase 2 trial testing temozolomide in Brain and Central Nervous System Tumors in 15 participants. Terminated before completion.

Timeline

15 February 2005

Primary endpoint
11 December 2007

11 December 2007

Quick facts

Lead sponsor	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	15 February 2005
Primary completion	11 December 2007
Estimated completion	11 December 2007
Sites	1 location across United States

Drugs / interventions tested

temozolomide (temozolomide) — full drug profile →
adjuvant therapy — full drug profile →
chemotherapy (chemotherapy) — full drug profile →
radiation therapy — full drug profile →

Conditions studied

Brain and Central Nervous System Tumors — all drugs for Brain and Central Nervous System Tumors →

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — full company profile →

Who can join

Adults 18 to 120, any sex, with Brain and Central Nervous System Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving temozolomide during and after radiation therapy may kill any tumor cells that remain after surgery and placement of Gliadel wafers. PURPOSE: This phase II trial is studying how well giving temozolomide during and after radiation therapy works in treating patients who have undergone previous surgery and placement of Gliadel wafers for newly diagnosed glioblastoma multiforme.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of temozolomide

Trials testing the same drug.

NCT05052957 — hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) · Phase 2 · recruiting
NCT04566380 — ONO-4538 Phase II Rollover Study (ONO-4538-98) · Phase 2 · recruiting
NCT04400188 — A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cel · Phase 1, PHASE2 · completed
NCT03514069 — Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma · Phase 1 · active not recruiting
NCT02168270 — Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma · Phase 1 · terminated

Other recruiting trials for Brain and Central Nervous System Tumors

Currently open trials in the same condition.

NCT00978458 — Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma · Phase 3 · active not recruiting

Other Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins trials

Trials by the same sponsor.

NCT07424222 — Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE) · Phase 1 · not yet recruiting
NCT06210854 — Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+ · Phase 2 · not yet recruiting
NCT07360119 — Total Pancreatectomy With Islet Autotransplantation (TPIAT) for High-Risk Patients With Pancreatic Tumors · NA · not yet recruiting
NCT07140315 — DK222 Study at Hopkins · Phase 1 · recruiting
NCT07071155 — Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Ove · EARLY_PHASE1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00238277 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Last refreshed: 27 June 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00238277.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing